Tumor necrosis factor, Interleukin-1 beta, and Interferon-gamma inflammatory signaling network (TNF/IL-1β/IFN-γ axis)

This target profile represents a complex network of three primary pro-inflammatory cytokines—Tumor Necrosis Factor (TNF), Interleukin-1 beta (IL-1β), and Interferon-gamma (IFN-γ)—and their associated downstream signaling cascades, including the NF-κB and JAK-STAT pathways [1, 2, 3]. These molecules function as master regulators of the inflammatory response, where TNF and IL-1β are central to innate immunity and acute inflammation, while IFN-γ is the hallmark cytokine of Th1-mediated adaptive immunity [4]. Dysregulation or overproduction of these cytokines is a fundamental driver of chronic autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as acute, life-threatening conditions like cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH) [1, 6]. Drugs targeting this network range from monoclonal antibodies that neutralize the cytokines themselves to small molecules that inhibit downstream kinases like JAK1, JAK2, and JAK3 [5]. While these interventions are highly effective in controlling systemic inflammation, they are associated with significant safety concerns, most notably an increased susceptibility to serious opportunistic infections and the potential for malignancy due to prolonged immunosuppression [5, 6].

Other names

Pro-inflammatory cytokine networkTh1/Innate inflammatory axisCytokine storm mediatorsTNF-alpha/IL-1-beta/IFN-gamma pathway

Therapeutic strategies include the use of monoclonal antibodies to neutralize circulating cytokines (e.g., anti-TNF, anti-IL-1β, anti-IFN-γ), receptor antagonists to block ligand binding (e.g., IL-1Ra), and small-molecule inhibitors to disrupt downstream intracellular signaling, particularly Janus kinase (JAK) inhibitors [4, 5, 6].